Kwaebibirem Pharmaceuticals is considering the production of a slimming drug that has a total life span of 17 years, seven () of which will be used in its implementation phase and the remaining ten (10) will be the revenue generating years. Phase I will take two years and cost $30 million. Phase II will take another two years and cost $40 million Phase III will take three years and cost $500 million. All costs for the individual phases will be made at the beginning of each phase. The product will then be launched at the beginning of the 8th year for another $400 million. Cash inflows of $483 million per year are expected to start at the end of the 8th year through to the 17th year. Cost of Capital is 20%. Determine the viability of this project using NPV, IRR and payback period